Needham Reiterates Buy on Absci, Maintains $7 Price Target
3/18/2026
Impact: 70
Healthcare
Needham analyst Gil Blum has reiterated a Buy rating on Absci (NASDAQ: ABSI) and has maintained a price target of $7 for the stock. No additional financial figures or strategic changes were mentioned in the article.
AI summary, not financial advice
Share: